Cetera Advisors LLC Altimmune, Inc. Transaction History

Cetera Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$8.22 - $13.81 $82,010 - $137,782	9,977 Added 19.63%	60,800 $618,000
Q4 2023 Feb 13, 2024	BUY	$2.14 - $11.62 $108,761 - $590,563	50,823 New	50,823 $571,000
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $20,102 - $37,835	-2,300 Reduced 18.55%	10,100 $166,000
Q3 2022 Nov 10, 2022	SELL	$10.67 - $22.41 $50,149 - $105,327	-4,700 Reduced 27.49%	12,400 $158,000
Q2 2022 Aug 11, 2022	SELL	$3.94 - $11.77 $5,516 - $16,478	-1,400 Reduced 7.57%	17,100 $200,000
Q1 2022 May 12, 2022	BUY	$5.9 - $9.45 $109,150 - $174,825	18,500 New	18,500 $113,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $300M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.